Stockscreener 앱 받기
60.77
8.00%
4.50
시간 외 거래:
60.61
-0.16
-0.26%
전일 마감가:
$56.27
열려 있는:
$57.285
하루 거래량:
3.30M
Relative Volume:
1.18
시가총액:
$8.51B
수익:
$1.09B
순이익/손실:
$233.57M
주가수익비율:
39.51
EPS:
1.5382
순현금흐름:
$327.01M
1주 성능:
+7.16%
1개월 성능:
-1.37%
6개월 성능:
+91.95%
1년 성능:
+312.56%
1일 변동 폭
$57.28
$62.80
1주일 범위
$54.89
$62.80
52주 변동 폭
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
60.77 | 7.88B | 1.09B | 233.57M | 327.01M | 1.5382 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Leerink reiterates Arrowhead Pharma stock rating on partner data By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Surges as Clinical Trial Doses First Patients - StocksToTrade
Arrowhead Pharma (ARWR) Rating Reiterated as 'Buy' by HC Wainwri - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6%Here's What Happened - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB - MarketBeat
Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Exit Recap: Whats the beta of Arrowhead Pharmaceuticals Inc stockWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Arrowhead (ARWR) FQ1 2026 revenue hits $264M as REDEMPLO approval marks commercial shift - MSN
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting - The Globe and Mail
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - MSN
Arrowhead Pharmaceuticals (NASDAQ: ARWR) holders back board but reject Say-on-Pay - Stock Titan
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential - TipRanks
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Recent Momentum Cools After A Strong Run - Yahoo Finance
Arrowhead’s bid to become a large-cap biotech - BioCentury
Arrowhead Pharmaceuticals (ARWR) price target increased by 17.24% to 59.24 - MSN
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach - Sahm
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma - Insider Monkey
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4%What's Changed - simplywall.st
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
How Arrowhead Pharmaceuticals Inc. (ARWR) Affects Rotational Strategy Timing - Stock Traders Daily
Fred Alger Management LLC Acquires New Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Boothbay Fund Management LLC - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4% After First Drug REDEMPLO Wins FDA ApprovalWhat's Changed - Sahm
Baker BROS. Advisors LP Purchases 731,588 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift - Insider Monkey
Analyst Upgrade: Can Arrowhead Pharmaceuticals Inc scale operations efficiently2026 Technical Overview & Precise Swing Trade Alerts - baoquankhu1.vn
225,000 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Integral Health Asset Management LLC - MarketBeat
Avoro Capital Advisors LLC Has $375.94 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
siRNA Therapeutics Market Poised for Rapid Growth to US$ 12.38 - openPR.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider James Hamilton Sells 10,000 Shares - MarketBeat
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock By Investing.com - Investing.com UK
Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock - Investing.com
Arrowhead Pharmaceuticals CMO Sells 10,000 Shares - TradingView
Arrowhead (NASDAQ: ARWR) CMO sells 10,000 shares in planned Form 4 trade - Stock Titan
Arrowhead Pharmaceuticals at Leerink Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc. - MarketBeat
Arrowhead Pharmaceuticals Q1 2026 earnings preview - MSN
ARWR SEC FilingsArrowhead Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Intech Investment Management LLC - MarketBeat
Piper Sandler maintains an overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) - MSN
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8%What's Next? - MarketBeat
Proposed 10,000-share sale via Merrill Lynch by ARWR (NASDAQ: ARWR) - Stock Titan
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference - MarketBeat
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Fisher Asset Management LLC Acquires 602,139 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):